CSIMarket Company Name, Ticker, Competitors, else..
 
Actuate Therapeutics Inc   (NASDAQ: ACTU)
 
Price: $1.4800 $0.11 8.029%
Day's High: $1.7300000190734863 Week Perf: -2.63 %
Day's Low: $ 1.33 30 Day Perf: 20.33 %
Volume (M): 1,322,900 52 Wk High: $ 8.55
Volume (M$): $ 0 52 Wk Avg: $4.05
Open: $1.45 52 Wk Low: $0.90



 Market Capitalization (Millions $) 35
 Shares Outstanding (Millions) 24
 Employees 12
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company is a clinical-stage biopharmaceutical firm developing therapies for difficult-to-treat cancers by inhibiting glycogen synthase kinase-3 beta (GSK-3β) with its lead drug candidate, elraglusib. It focuses on multiple cancer types, including metastatic pancreatic ductal adenocarcinoma, pediatric cancers, and metastatic melanoma, providing both injectable and oral formulations of elraglusib. The company is advancing elraglusib through clinical trials to address unmet medical needs in oncology.


   Company Address: 1751 River Run Fort Worth 76107 TX
   Company Phone Number: 887-8455   Stock Exchange / Ticker: NASDAQ ACTU


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Actuate Therapeutics Advances Treatment Paradigm for Metastatic Pancreatic Cancer with Promising Elraglusib Clinical ...

Published Mon, Sep 22 2025 1:24 PM UTC

In the ever-evolving landscape of oncology therapeutics, Actuate Therapeutics, Inc. (NASDAQ: ACTU) stands at the forefront, committed to addressing the formidable challenges posed by high-impact, difficult-to-treat cancers. On September 22, 2025, the biopharmaceutical company announced significant regulatory updates surrounding its investigational therapy, elraglusib, focuse...
Clinical Study

Actuate Therapeutics Pioneers Pediatric Oncology Positive Phase 1 Results for Elraglusib in Ewing Sarcoma

Published Fri, Jul 18 2025 1:24 PM UTC

Advancements in Pediatric OncologyRecent advancements in the field of pediatric oncology have captured the attention of researchers, practitioners, and investors alike. Actuate Therapeutics has made significant strides with its clinical program targeting Ewing Sarcoma a rare but aggressive form of cancer that predominantly affects children and adolescents. The completion of...
Clinical Study

Promising Advances in Metastatic Pancreatic Cancer Treatment Actuate Therapeutics Reports Positive Interim Phase 2 ...

Published Sun, Dec 29 2024 1:29 PM UTC

In a significant development in the fight against one of the deadliest forms of cancer, Actuate Therapeutics, Inc. (NASDAQ: ACTU) has announced positive interim results from its ongoing randomized Phase 2 trial investigating the efficacy of elraglusib in combination with standard chemotherapy for metastatic pancreatic ductal adenocarcinoma (mPDAC). The trial, designated as A...
Management Announcement

Actuate Therapeutics Set to Join Russell 2000 Amid Promising Advances in Pancreatic Cancer Treatment

Published Tue, Nov 26 2024 1:00 PM UTC

In a significant milestone for Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company dedicated to developing therapies for high-impact, difficult-to-treat cancers, the company is poised to be added to the Russell 2000 Index as part of the planned fourth quarter IPO additions. This inclusion is set to take effect after the U.S. market opens on ...
Clinical Study

Promising Initial Data on Elraglusib Combined with FOLFIRINOX for Metastatic Pancreatic Adenocarcinoma Presented at A...

Published Mon, Sep 16 2024 12:01 PM UTC

Actuate Therapeutics Unveils New Insights into Combating One of the Most Aggressive Cancers At the AACR Special Conference on Advances in Pancreatic Cancer Research, Actuate Therapeutics, Inc. revealed preliminary findings from a Phase 2 trial exploring the use of elraglusib and losartan in conjunction with the FOLFIRINOX regimen for patients with untreated metastatic pa...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 35.72
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.16
Working Capital Ratio 1.25
Leverage Ratio (MRQ) 4.26
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.91 $
Revenues (TTM) -
Cash Flow (TTM) 0.07 $
Cash 0.19 $
Book Value 0.04 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,704,484
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.